Zymeworks Common Stock Stock Fundamentals
| ZYME Stock | USD 14.09 0.33 2.29% |
Zymeworks Common Stock fundamentals help investors to digest information that contributes to Zymeworks Common's financial success or failures. It also enables traders to predict the movement of Zymeworks Stock. The fundamental analysis module provides a way to measure Zymeworks Common's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Zymeworks Common stock.
At present, Zymeworks Common's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 78.2 M, whereas Gross Profit is projected to grow to (63.6 M). Zymeworks | Select Account or Indicator |
Zymeworks Common Stock Company Shares Outstanding Analysis
Zymeworks Common's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Zymeworks Common Shares Outstanding | 68.88 M |
Most of Zymeworks Common's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zymeworks Common Stock is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Zymeworks Shares Outstanding Historical Pattern
Today, most investors in Zymeworks Common Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Zymeworks Common's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Zymeworks Common shares outstanding as a starting point in their analysis.
Zymeworks Common Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Zymeworks Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Zymeworks Common Stock has 68.88 M of shares currently outstending. This is 61.85% lower than that of the Biotechnology sector and 35.54% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 87.95% higher than that of the company.
Zymeworks Common Stock Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Zymeworks Common's current stock value. Our valuation model uses many indicators to compare Zymeworks Common value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Zymeworks Common competition to find correlations between indicators driving Zymeworks Common's intrinsic value. More Info.Zymeworks Common Stock is rated fifth in return on equity category among its peers. It is rated third in return on asset category among its peers . At present, Zymeworks Common's Return On Equity is projected to increase slightly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Zymeworks Common by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Zymeworks Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zymeworks Common's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Zymeworks Common could also be used in its relative valuation, which is a method of valuing Zymeworks Common by comparing valuation metrics of similar companies.Zymeworks Common is currently under evaluation in shares outstanding category among its peers.
Zymeworks Common Current Valuation Drivers
We derive many important indicators used in calculating different scores of Zymeworks Common from analyzing Zymeworks Common's financial statements. These drivers represent accounts that assess Zymeworks Common's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Zymeworks Common's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.7B | 2.4B | 1.1B | 512.4M | 715.5M | 800.3M | |
| Enterprise Value | 1.6B | 2.1B | 910.5M | 139.6M | 584.7M | 673.9M |
Zymeworks Common ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Zymeworks Common's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Zymeworks Common's managers, analysts, and investors.Environmental | Governance | Social |
Zymeworks Fundamentals
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (1.83) % | ||||
| Operating Margin | (2.14) % | ||||
| Current Valuation | 693.53 M | ||||
| Shares Outstanding | 68.88 M | ||||
| Shares Owned By Insiders | 0.08 % | ||||
| Shares Owned By Institutions | 98.89 % | ||||
| Number Of Shares Shorted | 4.21 M | ||||
| Price To Earning | (2.36) X | ||||
| Price To Book | 2.64 X | ||||
| Price To Sales | 15.97 X | ||||
| Revenue | 76.01 M | ||||
| Gross Profit | 203.78 M | ||||
| EBITDA | (129.96 M) | ||||
| Net Income | (118.67 M) | ||||
| Cash And Equivalents | 241.83 M | ||||
| Cash Per Share | 4.18 X | ||||
| Total Debt | 26.72 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 3.29 X | ||||
| Book Value Per Share | 5.27 X | ||||
| Cash Flow From Operations | (118.3 M) | ||||
| Short Ratio | 7.54 X | ||||
| Earnings Per Share | (1.49) X | ||||
| Target Price | 17.86 | ||||
| Number Of Employees | 294 | ||||
| Beta | 1.16 | ||||
| Market Capitalization | 993.21 M | ||||
| Total Asset | 580.88 M | ||||
| Retained Earnings | (677.44 M) | ||||
| Working Capital | 357.16 M | ||||
| Net Asset | 580.88 M |
About Zymeworks Common Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Zymeworks Common Stock's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zymeworks Common using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zymeworks Common Stock based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 3.7 M | 3.5 M | |
| Total Revenue | 76 M | 78.2 M | |
| Cost Of Revenue | 143 M | 110.8 M | |
| Stock Based Compensation To Revenue | 0.11 | 0.10 | |
| Sales General And Administrative To Revenue | 0.93 | 1.24 | |
| Research And Ddevelopement To Revenue | 1.89 | 3.69 | |
| Capex To Revenue | 0.05 | 0.05 | |
| Revenue Per Share | 1.10 | 1.19 | |
| Ebit Per Revenue | (1.82) | (1.91) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zymeworks Common Stock is a strong investment it is important to analyze Zymeworks Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zymeworks Common's future performance. For an informed investment choice regarding Zymeworks Stock, refer to the following important reports:Check out Zymeworks Common Piotroski F Score and Zymeworks Common Altman Z Score analysis. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zymeworks Common. If investors know Zymeworks will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zymeworks Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.49) | Revenue Per Share 0.831 | Quarterly Revenue Growth (0.03) | Return On Assets (0.15) | Return On Equity (0.29) |
The market value of Zymeworks Common Stock is measured differently than its book value, which is the value of Zymeworks that is recorded on the company's balance sheet. Investors also form their own opinion of Zymeworks Common's value that differs from its market value or its book value, called intrinsic value, which is Zymeworks Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zymeworks Common's market value can be influenced by many factors that don't directly affect Zymeworks Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zymeworks Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zymeworks Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zymeworks Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.